Clinical Trial Update: A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) [Phase 2, Phase 3]

View source ↗

Summary

Describes a pediatric Phase 2/3 study of intravenous efgartigimod in children aged 12 to under 18 with chronic immune thrombocytopenia that is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Efgartigimod (efgartigimod)

Snippet

Sponsor: argenx | Conditions: Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia | Phase 2, Phase 3 | Status: RECRUITING